V. Hirsh

Association Between Tumor Egfr and Kras Mutation Status and Clinical Outcomes in Nsclc Patients Randomized to Sorafenib Plus Best Supportive Care (BSC) or Bsc Alone: Subanalysis of the Phase III Mission Trial

Tony Mok, Luis Paz‐Ares, Yi‐Long Wu et al. · Annals of Oncology · 2012 · 37 citations · Full text

Medicine, Genetics, Oncology +15

P2.07-029 CheckMate 169: Safety/Efficacy of Nivolumab in Canadian Pretreated Advanced NSCLC (including Elderly and PS 2) Patients

Rosalyn A. Juergens, Quincy S. Chu, J. Rothenstein et al. · Journal of Thoracic Oncology · 2017 · 15 citations

Medicine, Geriatric Medicine, Pharmacotherapy +3

A phase III, randomized, double-blind, placebo-controlled study of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated subjects with locally advanced or metastatic, nonsquamous, non-small cell lung cancer (NSCLC) .

Alan Sandler, Joan H. Schiller, V. Hirsh et al. · Journal of Clinical Oncology · 2011 · 11 citations

Medicine, Oncology, Pharmacology +16